Bioengineer Gang Bao uses gene editing to repair up to 40 percent of bone marrow cells from patients
Scientists have successfully used gene editing to repair 20 to 40 percent of stem and progenitor cells taken from the peripheral blood of patients with sickle cell disease, according to Rice University bioengineer Gang Bao.
Bao, in collaboration with Baylor College of Medicine, Texas Children’s Hospital and Stanford University, is working to find a cure for the hereditary disease. A single DNA mutation causes the body to make sticky, crescent-shaped red blood cells that contain abnormal hemoglobin and can block blood flow in limbs and organs.
In his talk at the annual American Association for the Advancement of Science meeting in Austin Feb. 16, Bao revealed results from a series of tests to see whether CRISPR/Cas9-based editing can fix the mutation. His presentation was part of a scientific session titled “Gene Editing and Human Identity: Promising Advances and Ethical Challenges.”
“Sickle cell disease is caused by a single mutation in the beta-globin gene (in the stem cell’s DNA),” he said. “The idea is to correct that particular mutation, and then stem cells that have the correction would differentiate into normal blood cells, including red blood cells. Those will then be healthy blood cells.”
Bao’s lab collaborated with Vivien Sheehan, an assistant professor of pediatrics and hematology at Baylor and a member of the sickle cell program at Texas Children’s, to collect stem and progenitor cells (CD34-positive cells) from patients with the disease. These were then edited in the Bao lab with CRISPR/Cas9 together with a custom template, a piece of DNA designed to correct the mutation.
The gene-edited cells were injected into the bone marrow of immunodeficient mice and tested after 19 weeks to see how many retained the edit. “The rate of repair remained stable, which is great,” Bao said. This engraftment study was carried out in the lab of Matt Porteus, an associate professor of pediatrics at Stanford.
Another major finding of the study is that the CRISPR/Cas9 system could introduce large alterations to the genes in patients’ cells, in addition to small mutations or deletions. These off-target effects could cause a disease.
The findings, part of an upcoming paper, are a step toward treating sickle cell disease. Obstacles in the way of a cure include optimizing the CRISPR/Cas9 system to eliminate off-target effects, as well as finding a way to further increase the amount of gene-corrected stem cells.
Bao pointed out that researchers still don’t know whether repairing as much as 40 percent of the cells is enough to cure a patient. “We’d like to say, ‘Yes,’” he said, “but we don’t really know yet. That’s something we hope to learn from an eventual clinical trial.”
The Latest on: Sickle cell disease
- Sickle Cell Disease Association of America Company Profile & Social Media Wall Press Room - Press Releases on February 20, 2019 at 5:42 am
The Sickle Cell Disease Association of America, Inc. (SCDAA) celebrates 41 years of relentless service this year. Today it serves as the nations only nonprofit organization working full-time to resolv... […]
- Sickle Cell Care Advocates Ramp Up Efforts For 2019 on February 19, 2019 at 6:07 pm
Our volunteers are working very hard. They have a passion for what they do. BSCA finds that when a person knows someone who is personally affected by sickle cell disease, empathy and action come to th... […]
- Jo-Wilfried Tsonga withdraws from Indian Wells with serious blood disorder sickle cell disease on February 19, 2019 at 8:59 am
Tennis ace will not feature in tournament due to condition which affects him particularly hard after flying The blood disorder causes people to produce odd-shaped red blood cells. They do not live as ... […]
- GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease on February 19, 2019 at 5:00 am
SOUTH SAN FRANCISCO, Calif., Feb 19, 2019 (GLOBE NEWSWIRE via COMTEX) -- --The Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) Supports Novel Projects Aimed at Improving Access ... […]
- Sickle Cell Disease Treatment Market Is Touching New Levels – AddMedica, Pfizer, Novartis, Bluebird bio on February 18, 2019 at 7:41 am
A new business intelligence report released by Advance Market Analytics with title "Global Sickle Cell Disease Treatment Market Insights, Forecast to 2025" has abilities to raise as the most significa... […]
- Sending A Child With Sickle Cell Disease Off To College on February 17, 2019 at 4:00 pm
Teemer Barry is a freshman at The University of Maryland - Eastern Shore. Credit Leoneda Inge / WUNC Editor's Note: WUNC Race and Southern Culture Reporter Leoneda Inge shares a personal account of he... […]
- In New Haven, fighting a deadly disease on February 17, 2019 at 4:58 am
He’s just interested in helping children with sickle cell disease live a better life, using the house at 1389 Chapel St., across from the Yale New Haven Hospital’s St. Raphael campus as a base for the ... […]
- STUDY: Buhari Suffering From A Combination Of Prostate Cancer, Sickle Cell, Crohn’s Disease And Dementia on February 15, 2019 at 4:22 am
“Data analysis suggests a certainty of the prostate cancer diagnosis, a high probability of Crohn’s disease, and a likelihood of both dementia and sickle cell anemia. Each condition in itself ... […]
- This Sickle Cell Warrior is always fighting his battle with a smile on February 13, 2019 at 1:30 pm
Fourteen-year old Cody, has sickle cell disease, a disease that causes red blood cells to be misshapen and break down faster than normal red blood cells, but he isn't letting this stop his shine. […]
- Sickle Cell Pioneer Dr Doris Wethers Dead at 91 on February 12, 2019 at 12:29 pm
Doris Louise Wethers, MD, well known for her research on sickle cell disease, died January 28 in Yonkers, New York, from complications of a stroke. She was 91. Wethers also helped blaze a trail for Af... […]
via Google News and Bing News